<DOC>
	<DOCNO>NCT01453205</DOCNO>
	<brief_summary>The overall purpose study determine MEDI-551 , use combination salvage chemotherapy , Ifosfamide-carboplatin-etoposide ( ICE ) Dexamethasone-cytarabine ( DHAP ) patient relapse refractory DLBCL eligible Autologous Stem Cell Transplant ( ASCT ) , superior efficacy compare rituximab population .</brief_summary>
	<brief_title>A Phase 2 , Multicenter , Randomized , Open-label Study MEDI-551 Adults With Relapsed Refractory Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm aggressive Bcell DLBCL , include FL transform DLBCL &amp; Grade III FL Relapsed refractory least one treatment contain rituximab another antiCD20 base immunotherapy combine anthracycline anthracenedionebased chemotherapy Eligible ASCT Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy ≥ 12 week Adequate hematological function Any chemotherapy , radiotherapy , immunotherapy , biologic , investigational hormonal therapy treatment lymphoma within 28 day prior treatment Previous cancer therapy DLBCL anthracycline anthracenedione base chemoimmunotherapy , monotherapy rituximab prior first line therapy and/or maintenance therapy , limited field radiotherapy Prior autologous allogeneic SCT New York Heart Association ≥ Class II congestive heart failure ; Clinically significant abnormality ECG History invasive malignancy within 5 year except localized/in situ , carcinomas cervical carcinoma situ . Evidence active infection Documented current central nervous system involvement leukemia lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lymphoma , Non-Hodgkin 's Lymphoma , Diffuse Large B-Cell Lymphoma , DLBCL , B-Cell Malignancy , anti-CD19 , monoclonal antibody , second line , ASCT , Refractory</keyword>
</DOC>